Cipla
- All
- News
- Videos
-
Cipla, Glenmark Recall Asthma Drugs Made In Indore From US Market
Drug makers Cipla and Glenmark are recalling products from the American market due to manufacturing issues, according to the US health regulator.
-
Cipla Recalls 6 Batches Of Bronchospasm Treatment Inhalation Aerosol In US
Pharmaceutical firm Cipla Ltd on Friday said it is voluntarily recalling six batches of Albuterol Sulfate inhalation aerosol in the US market due to container defect.
-
Five Indian Drugmakers To Jointly Start Trial Of Merck & Co's Covid Drug
Fivegeneric drugmakers, including Cipla and Dr Reddy's Laboratories, said on Tuesday they would jointly conduct a clinical trial of Merck & Co's anti-viral drug to treat mild COVID-19 in non-hospitalised patients in the country.
-
Moderna Approved For Emergency Use, 4th Vaccine Okayed By India
The government on Tuesday cleared the fourth vaccine for emergency use in the country, the US-made Moderna.
-
Delhi's LNJP Hospital Begins Free Antibody Cocktail Therapy For Covid Patients
The Monoclonal Antibody Cocktail used to treat mild to moderate "high risk" Covid patients is now available at Delhi's Lok Nayak Jai Prakash Narayan Hospital (LNJP) for free.
-
Cipla Close To Committing Over $1 Billion For Moderna Booster Vaccine In India: Report
Seeking fast-track approvals to bring Moderna's single-dose COVID-19 booster vaccine in India expeditiously, Cipla has requested the government for indemnification and exemptions from price capping, bridging trials and basic customs duty.
-
Moderna, Pfizer Covid Vaccines Likely In India Next Year: Report
Moderna is expecting to launch a single-dose COVID-19 vaccine in India next year and is in talks with Cipla among other firms, while Pfizer is ready to offer 5 crore shots in 2021 but it wants significant regulatory relaxations.
-
3 Indian Firms To Make, Sell US's Eli Lilly's Baricitinib Drug For Covid Treatment
Eli Lilly and Co said on Monday it had signed licensing agreements with three Indian generic drugmakers to expand the availability of its arthritis drug baricitinib in the country for treating COVID-19 patients.
-
Cipla To Make, Sell US's Eli Lilly's Baricitinib Drug For Covid Treatment
Indian drugmaker Cipla Ltd said on Monday it has entered into a licensing agreement with U.S. company Eli Lilly and Co to make and sell Lilly's arthritis drug baricitinib for the treatment of COVID-19 patients.
-
Merck Taps 5 Indian Drugmakers To Expand Covid Drug Production
Merck & Co Inc said on Tuesday it had partnered with five Indian generic drugmakers, including Cipla Ltd and Sun Pharmaceutical Industries Ltd, to expand production and access to its experimental COVID-19 drug.
-
Cipla Doubles Remdesivir Production In India For "Unprecedented" Demand
India's Cipla Ltd has doubled production of COVID-19 medication remdesivir to help meet "unprecedented demand" as the country battles a massive second wave of infections, the drugmaker said on Tuesday.
-
Cambridge University Names Chemistry Department After Cipla's Yusuf Hamied
In recognition of his “generous benefaction”, the University of Cambridge announced on Tuesday that its chemistry department will be named after Indian pharmaceutical major Cipla's non-executive chairman Yusuf Hamied until 2050.
-
Indian Demand For COVID-19 Drug Remdesivir Rising Sharply: Cipla
Demand for COVID-19 antiviral drug remdesivir is rising sharply in India, a top executive at drugmaker Cipla Ltd said on Monday, even as experts remain divided over its effectiveness.
-
India's Shortage Of Remdesivir Is Easing, Says Producer Cipla
India's supply of antiviral drug remdesivir and generic equivalents is stabilising after shortages of the vital COVID-19 medicine at hospitals, according to a top executive at one of the country's big drugmakers, Cipla Ltd.
-
Cipla Set To Launch Favipiravir Drug For Treatment Of COVID Patients
Pharmaceutical firm Cipla is all set to launch Favipiravir, developed by the Council of Scientific and Industrial Research (CSIR) in a cost-effective process, for the treatment of COVID-19 patients, according to an official statement on Thursday.
-
Cipla, Glenmark Recall Asthma Drugs Made In Indore From US Market
Drug makers Cipla and Glenmark are recalling products from the American market due to manufacturing issues, according to the US health regulator.
-
Cipla Recalls 6 Batches Of Bronchospasm Treatment Inhalation Aerosol In US
Pharmaceutical firm Cipla Ltd on Friday said it is voluntarily recalling six batches of Albuterol Sulfate inhalation aerosol in the US market due to container defect.
-
Five Indian Drugmakers To Jointly Start Trial Of Merck & Co's Covid Drug
Fivegeneric drugmakers, including Cipla and Dr Reddy's Laboratories, said on Tuesday they would jointly conduct a clinical trial of Merck & Co's anti-viral drug to treat mild COVID-19 in non-hospitalised patients in the country.
-
Moderna Approved For Emergency Use, 4th Vaccine Okayed By India
The government on Tuesday cleared the fourth vaccine for emergency use in the country, the US-made Moderna.
-
Delhi's LNJP Hospital Begins Free Antibody Cocktail Therapy For Covid Patients
The Monoclonal Antibody Cocktail used to treat mild to moderate "high risk" Covid patients is now available at Delhi's Lok Nayak Jai Prakash Narayan Hospital (LNJP) for free.
-
Cipla Close To Committing Over $1 Billion For Moderna Booster Vaccine In India: Report
Seeking fast-track approvals to bring Moderna's single-dose COVID-19 booster vaccine in India expeditiously, Cipla has requested the government for indemnification and exemptions from price capping, bridging trials and basic customs duty.
-
Moderna, Pfizer Covid Vaccines Likely In India Next Year: Report
Moderna is expecting to launch a single-dose COVID-19 vaccine in India next year and is in talks with Cipla among other firms, while Pfizer is ready to offer 5 crore shots in 2021 but it wants significant regulatory relaxations.
-
3 Indian Firms To Make, Sell US's Eli Lilly's Baricitinib Drug For Covid Treatment
Eli Lilly and Co said on Monday it had signed licensing agreements with three Indian generic drugmakers to expand the availability of its arthritis drug baricitinib in the country for treating COVID-19 patients.
-
Cipla To Make, Sell US's Eli Lilly's Baricitinib Drug For Covid Treatment
Indian drugmaker Cipla Ltd said on Monday it has entered into a licensing agreement with U.S. company Eli Lilly and Co to make and sell Lilly's arthritis drug baricitinib for the treatment of COVID-19 patients.
-
Merck Taps 5 Indian Drugmakers To Expand Covid Drug Production
Merck & Co Inc said on Tuesday it had partnered with five Indian generic drugmakers, including Cipla Ltd and Sun Pharmaceutical Industries Ltd, to expand production and access to its experimental COVID-19 drug.
-
Cipla Doubles Remdesivir Production In India For "Unprecedented" Demand
India's Cipla Ltd has doubled production of COVID-19 medication remdesivir to help meet "unprecedented demand" as the country battles a massive second wave of infections, the drugmaker said on Tuesday.
-
Cambridge University Names Chemistry Department After Cipla's Yusuf Hamied
In recognition of his “generous benefaction”, the University of Cambridge announced on Tuesday that its chemistry department will be named after Indian pharmaceutical major Cipla's non-executive chairman Yusuf Hamied until 2050.
-
Indian Demand For COVID-19 Drug Remdesivir Rising Sharply: Cipla
Demand for COVID-19 antiviral drug remdesivir is rising sharply in India, a top executive at drugmaker Cipla Ltd said on Monday, even as experts remain divided over its effectiveness.
-
India's Shortage Of Remdesivir Is Easing, Says Producer Cipla
India's supply of antiviral drug remdesivir and generic equivalents is stabilising after shortages of the vital COVID-19 medicine at hospitals, according to a top executive at one of the country's big drugmakers, Cipla Ltd.
-
Cipla Set To Launch Favipiravir Drug For Treatment Of COVID Patients
Pharmaceutical firm Cipla is all set to launch Favipiravir, developed by the Council of Scientific and Industrial Research (CSIR) in a cost-effective process, for the treatment of COVID-19 patients, according to an official statement on Thursday.
